Calroy Health Sciences has introduced Cartigenix HP®, a dietary supplement that aims to enhance joint health through cartilage regeneration. This product is backed by three significant human studies involving over 1,700 participants, demonstrating an average 67% reduction in pain scores and a 50% increase in walking distance within 90 days. The most rigorous study, conducted by Vaidya in 2025, revealed measurable cartilage regeneration biomarkers, a notable advancement over traditional joint supplements like glucosamine and chondroitin, which lack similar evidence. Cartigenix HP® features a proprietary blend called RestorCel®, comprising 13 bioactive compounds, including serratol from Boswellia serrata, known for its efficacy in joint health. Clinicians have expressed optimism about this new formulation, as it provides tangible, peer-reviewed outcomes to support patient recommendations. The studies indicate that users can expect noticeable improvements in joint comfort as early as 15 days, reinforcing the product's potential as a viable option for those seeking effective joint health solutions.